Lyra Therapeutics, Inc. Quarterly Debt-to-equity in % from Q3 2020 to Q3 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Lyra Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2020 to Q3 2024.
Lyra Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 109 %, a 199% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q3 2024	109	+72.8	+199%	Sep 30, 2024
Q2 2024	77	+44.4	+136%	Jun 30, 2024
Q1 2024	51.7	+20.8	+67.1%	Mar 31, 2024
Q4 2023	42.7	+8.63	+25.3%	Dec 31, 2023
Q3 2023	36.5	-0.3	-0.82%	Sep 30, 2023
Q2 2023	32.6	-9.6	-22.8%	Jun 30, 2023
Q1 2023	30.9	-20.9	-40.4%	Mar 31, 2023
Q4 2022	34.1	+2.42	+7.65%	Dec 31, 2022
Q3 2022	36.8	+16.1	+77.8%	Sep 30, 2022
Q2 2022	42.2	+29	+220%	Jun 30, 2022
Q1 2022	51.8	+44	+568%	Mar 31, 2022
Q4 2021	31.6	+9.1	+40.4%	Dec 31, 2021
Q3 2021	20.7	+53.9		Sep 30, 2021
Q2 2021	13.2			Jun 30, 2021
Q1 2021	7.75			Mar 31, 2021
Q4 2020	22.5			Dec 31, 2020
Q3 2020	-33.1			Sep 30, 2020

* An asterisk sign (*) next to the value indicates that the value is likely invalid.